Mutations predict response to pembrolizumab across multiple tumour types
Two-year study shows efficacy of immunotherapy drug in 12 mismatch-repair deficient cancers that failed to respond to prior treatment.
Several markers have been identified that can predict response to the immunotherapy pembrolizumab in specific tumour types. But a universal marker across all tumour types has not been established.
In research published in Science (8 June 2017), a team enrolled 86 patients with 12 different cancer types whose disease had progressed despite previous treatment to receive pembrolizumab for up to two years. All the patients had mismatch-repair (MMR) deficiencies, meaning they had mutations in genes involved in repairing DNA errors.
The team found that 66 (77%) of the 86 patients (95% confidence interval, 66–85%) achieved disease control for at least 12 weeks, including 18 (21%) patients who had a complete response.
Given that tests for MMR-deficiency are already available, the researchers predict that in future it will become standard to test for MMR deficiency in patients with refractory cancer, regardless of tumour type.
Citation: Clinical Pharmacist DOI: 10.1211/CP.2017.20203057
Recommended from Pharmaceutical Press
An innovative book which presents statistics in the context of clinical trials conducted during pharmaceutical drug development.£38.00Buy now